Various guidelines recommended angiotensin converting enzyme (ACE) inhibitors or angiotensin Ⅱ receptor-1 blockers (ARBs) for hypertensive patients with diabetes on the basis of the cardiac- and reno-protective effects of these drugs. However, these recommendations could not be extrapolated to Japanese patients, because Japan has been known as a country with a low incidence of coronary artery disease and a high incidence of cerebrovascular disease. Furthermore, calcium channel blockers (CCBs) also were protective against renal function as well as ACE inhibitors in Japanese diabetic hypertensive patients. This study will test whether ARBs or CCBs are superior in treating Japanese diabetic hypertensive patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
1,150
valsartan 80 to 160 mg daily
Amlodipine 5 to 10 mg daily.
Department of Cardiology, Nagoya University Graduate School of Medicine
Nagoya, Aichi-ken, Japan
Composite cardiovascular events including fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, admission due to heart failure, coronary intervention and sudden cardiac death
Time frame: At least 3 years of mean follow up period
total death
Time frame: At least 3 years of mean follow up period
cardiac function evaluated by ultrasonography
Time frame: At least 3 years of mean follow up period
incidence of atrial fibrillation/flutter
Time frame: At least 3 years of mean follow up period
control of blood glucose
Time frame: At least 3 years of mean follow up period
renal function
Time frame: At least 3 years of mean follow up period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.